Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 595.00Impact Factor 2024: 3.4
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease.
The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease.
Authors: Piaceri, Irene | Bagnoli, Silvia | Lucenteforte, Ersilia | Mancuso, Michelangelo | Tedde, Andrea | Siciliano, Gabriele | Piacentini, Silvia | Bracco, Laura | Sorbi, Sandro | Nacmias, Benedetta
Article Type: Short Communication
Abstract: A common polymorphism (rs3851179) in the PICALM (phosphatidylinositol-binding clathrin assembly protein) gene has been recently associated with reduced risk of developing late-onset Alzheimer's disease (LOAD). We analyzed the genotype and allele distributions of the PICALM polymorphism in 813 Italian subjects, including LOAD patients and centenarians. The segregation of the PICALM rs3851179 showed no statistically significant difference between LOAD cases and controls. The implication of a genetic variant at PICALM is confirmed for the first time, in centenarians, thus suggesting a possible role in longevity.
Keywords: Alzheimer's disease, apolipoprotein E, centenarian, genetic variation, PICALM
DOI: 10.3233/JAD-2011-101791
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 409-413, 2011
Authors: Bernardi, Livia | Anfossi, Maria | Gallo, Maura | Geracitano, Silvana | Colao, Rosanna | Puccio, Gianfranco | Curcio, Sabrina A.M. | Frangipane, Francesca | Mirabelli, Maria | Clodomiro, Alessandra | Di Lorenzo, Raffaele | Smirne, Nicoletta | Maletta, Raffaele | Iapaolo, David | Bruni, Amalia C.
Article Type: Short Communication
Abstract: Prion protein (PRNP) gene mutations have recently been associated with clinical pictures resembling Frontotemporal dementia (FTD). We describe a novel seven extra-repeat insertional mutation in the PRNP gene in a family affected by early-onset autosomal dominant FTD previously reported as caused by a PSEN1 mutation in which there was inconsistency between clinical picture and genotype. Both mutations were pathogenic and showed a variable penetrance when present separately; when occurring together, the onset was very early, within the third decade of life. Genetic screening of the PRNP gene becomes of major importance in early onset autosomal dominant dementia.
Keywords: Frontotemporal dementia, genetic polymorphism, penetrance, presenilin-1, prion protein
DOI: 10.3233/JAD-2011-101890
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 415-419, 2011
Authors: García-Mesa, Yoelvis | López-Ramos, Juan Carlos | Giménez-Llort, Lydia | Revilla, Susana | Guerra, Rafael | Gruart, Agnès | LaFerla, Frank M. | Cristòfol, Rosa | Delgado-García, José M. | Sanfeliu, Coral
Article Type: Research Article
Abstract: Physical exercise is considered to exert a positive neurophysiological effect that helps to maintain normal brain activity in the elderly. Expectations that it could help to fight Alzheimer's disease (AD) were recently raised. This study analyzed the effects of different patterns of physical exercise on the 3xTg-AD mouse. Male and female 3xTg-AD mice at an early pathological stage (4-month-old) have had free access to a running wheel for 1 month, whereas mice at a moderate pathological stage (7-month-old) have had access either during 1 or 6 months. The non-transgenic mouse strain was used as a control. Parallel animal groups were …housed in conventional conditions. Cognitive loss and behavioral and psychological symptoms of dementia (BPSD)-like behaviors were present in the 3xTg-AD mice along with alteration in synaptic function and ong-term potentiation impairment in vivo. Brain tissue showed AD-pathology and oxidative-related changes. Disturbances were more severe at the older age tested. Oxidative stress was higher in males but other changes were similar or higher in females. Exercise treatment ameliorated cognitive deterioration and BPSD-like behaviors such as anxiety and the startle response. Synaptic changes were partially protected by exercise. Oxidative stress was reduced. The best neuroprotection was generally obtained after 6 months of exercise in 7-month-old 3xTg-AD mice. Improved sensorimotor function and brain tissue antioxidant defence were induced in both 3xTg-AD and NonTg mice. Therefore, the benefits of aerobic physical exercise on synapse, redox homeostasis, and general brain function demonstrated in the 3xTg-AD mouse further support the value of this healthy life-style against neurodegeneration. Show more
Keywords: 3xTg-AD mouse, age, Alzheimer's disease, amyloid-β, behavior, cognition, electrophysiology, gender, oxidative stress, PHF-tau, voluntary exercise
DOI: 10.3233/JAD-2011-101635
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 421-454, 2011
Authors: Filippi, Massimo | Agosta, Federica
Article Type: Research Article
Abstract: Patients with Alzheimer's disease (AD) experience a brain network breakdown, reflecting disconnection at both the structural and functional system level. Resting-state (RS) functional MRI (fMRI) studies demonstrated that the regional coherence of the fMRI signal is significantly altered in patients with AD and amnestic mild cognitive impairment. Diffusion tensor (DT) MRI has made it possible to track fiber bundle projections across the brain, revealing a substantially abnormal interplay of “critical” white matter tracts in these conditions. The observed agreement between the results of RS fMRI and DT MRI tractography studies in healthy individuals is encouraging and offers interesting hypotheses to …be tested in patients with AD, aMCI, and other dementias in order to improve our understanding of their pathobiology in vivo. In this review, we describe the major findings obtained in AD using RS fMRI and DT MRI tractography, and discuss how the relationship between structure and function of the brain networks in AD may be better understood through the application of MR-based technology. This research endeavor holds a great promise in clarifying the mechanisms of cognitive decline in complex chronic neurodegenerative disorders. Show more
Keywords: Alzheimer's disease, amnestic mild cognitive impairment, diffusion tensor MRI, diffusion tensor MRI tractography, functional connectivity, resting-state functional MRI, structural connectivity
DOI: 10.3233/JAD-2011-101854
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 455-474, 2011
Authors: Bennet, Anna M. | Reynolds, Chandra A. | Eriksson, Ulrika K. | Hong, Mun-Gwan | Blennow, Kaj | Gatz, Margaret | Alexeyenko, Andrey | Pedersen, Nancy L. | Prince, Jonathan A.
Article Type: Research Article
Abstract: We performed a survey of sequence variation in a series of 20 genes involved in inflammation-related pathways for association with dementia risk in twin and unrelated case-control samples consisting in total of 1462 Swedish dementia cases and 1929 controls. For a total of 218 tested genetic markers, strong evidence was obtained implicating a region near AGER and NOTCH4 on chromosome 6p with replication across both samples and maximum combined significance at marker rs1800625 (OR = 1.37, 95% CI 1.19–1.56, p = 1.36 × 10−6 . Imputation of the associated genomic interval provided an improved signal at rs8365, near the 3′UTR …of AGER (p = 7.34 × 10−7 . The associated region extends 120 kb encompassing 11 candidate genes. While AGER encodes a key receptor for amyloid-β protein, an analysis of network context based upon genes now confirmed to contribute to dementia risk (AβPP, PSEN1, PSEN2, CR1, CLU, PICALM, and APOE) suggested strong functional coupling to NOTCH4, with no significant coupling to the remaining candidates. The implicated region occurs in the broad HLA locus on chromosome 6p, but associated markers were not in strong LD with known variants that regulate HLA gene function, suggesting that this may represent a signal distinct from immune-system pathways. Show more
Keywords: Association, dementia, gene, inflammation NOTCH4
DOI: 10.3233/JAD-2011-101848
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 475-484, 2011
Authors: Hsu, Chih-Cheng | Wahlqvist, Mark L. | Lee, Meei-Shyuan | Tsai, Hsin-Ni
Article Type: Research Article
Abstract: To determine incidence of dementia in type 2 diabetic (T2DM) patients, and whether there are adverse or favorable effects of oral agents (OA) in DM, we obtained a representative cohort of 800,000 from Taiwan's National Health Insurance database. Those who, as of on January 1, 2000, were 50 years or older and dementia free (n = 127,209) were followed until December 31, 2007, in relation to absence (n = 101,816) or presence (n = 25,393) of T2DM, and whether any OA was used. Dementia was ascertained by ICD9-CM or A-code. Dementia incidence densities (DID) and fully adjusted Cox proportional hazard …models were used to estimate association between dementia, DM, and OA. Notably, DID (per 10,000 person-years) was markedly increased with DM (without medication), compared to DM free subjects (119 versus 46). Using non-DM as reference, the adjusted hazard ratios (HRs) (95% confidence interval) for DM without and with OA were 2.41 (2.17–2.66) and 1.62 (1.49–1.77), respectively. For T2DM, compared with no medication, sulfonylureas alone reduced the HR from 1 to 0.85 (0.71–1.01), metformin alone to 0.76 (0.58–0.98), while with combined oral therapy the HR was 0.65 (0.56–0.74). Adjustments included cerebrovascular diseases so that non-stroke related dementias were found to be decreased in DM with sulfonylurea and metformin therapy. T2DM increases the risk of dementia more than 2-fold. On the other hand, sulfonylureas may decrease the risk of dementia, as does metformin; together, these 2 OAs decrease the risk of dementia in T2DM patients by 35% over 8 years. Show more
Keywords: Alzheimer's disease, anti-diabetic medication, dementia, type 2 diabetes
DOI: 10.3233/JAD-2011-101524
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 485-493, 2011
Authors: Schöll, Michael | Almkvist, Ove | Bogdanovic, Nenad | Wall, Anders | Långström, Bengt | Viitanen, Matti | Nordberg, Agneta
Article Type: Research Article
Abstract: Studies in carriers of mutations that cause early-onset familial Alzheimer's disease (eoFAD) are of significant interest. We showed previously that regional glucose hypometabolism could be detected many years before disease onset in presenilin 1 (PSEN1) mutation carriers. Here we studied four members of a family with a Met146Val PSEN1 mutation, two symptomatic carriers and two non-carriers, longitudinally with 18 F-FDG PET over a period of about two and four years, respectively. The two mutation carriers showed global cortical glucose hypometabolism over time with the most distinct decline occurring in the posterior cingulate, the parietal and parietotemporal cortex, which was also …observed when compared with a group of 23 healthy controls and a group 27 sporadic Alzheimer's disease (sAD) patients. This decline correlated with cognitive deterioration over time as measured by neuropsychological tests. Postmortem examination of brain tissue revealed substantially elevated levels of AD type neuropathology in terms of neuritic plaques and neurofibrillary tangles in the two mutation carriers compared with a reference group of sAD patients. In the mutation carriers, the amount of neuritic plaques but not neurofibrillary tangles correlated hereby significantly with regional glucose metabolism as measured by 18 F-FDG on the last scanning occasions, which were performed four and approximately five years before death, respectively. We here show that FDG PET can depict in vivo the aggressive disease progression in eoFAD mutation carriers in relationship to neuropathology. Show more
Keywords: Early-onset familial Alzheimer's disease, FDG, longitudinal studies, neuritic plaques, neurofibrillary tangles, postitron emission tomography, postmortem pathology, presenilin 1
DOI: 10.3233/JAD-2011-101563
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 495-506, 2011
Authors: Igarashi, Miki | Ma, Kaizong | Gao, Fei | Kim, Hyung-Wook | Rapoport, Stanley I. | Rao, Jagadeesh S.
Article Type: Research Article
Abstract: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by brain deposition of senile (neuritic) plaques containing amyloid-β, neurofibrillary tangles, synaptic loss, neuroinflammation, and overexpression of arachidonic acid (AA, 20:4n-6) metabolizing enzymes. Lipid concentration changes have been reported in different brain regions, but often partially or as a percent of the total concentration. In this study, we measured absolute concentrations (per gram wet weight) of a wide range of lipids in postmortem prefrontal cortex (Brodmann area 9) from 10 AD patients and 9 non-AD controls. Mean total brain lipid, phospholipid, cholesterol, and triglyceride concentrations did not differ significantly between AD …and controls. There was a significant 73% decrease in plasmalogen choline, but no difference in other measured phospholipids. Fatty acid concentrations in total phospholipid did not differ from control. However, docosahexaenoic acid (DHA, 22:6n-3) was reduced in ethanolamine glycerophospholipid and choline glycerophospholipid, but increased in phosphatidylinositol. AA was reduced in choline glycerophospholipid, but increased in phosphatidylinositol, while docosatetraenoic acid (22:4n-6), an AA elongation product, was reduced in total brain lipid, cholesteryl ester and triglyceride. These lipid changes, which suggest extensive membrane remodeling, may contribute to membrane instability and synaptic loss in AD and reflect neuroinflammation. Show more
Keywords: Alzheimer's disease, arachidonic, brain, cholesteryl ester, docosahexaenoic acid, lipid, phospholipid, plasmalogen, postmortem
DOI: 10.3233/JAD-2011-101608
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 507-517, 2011
Authors: Hong, Yun Jeong | Yoon, Bora | Shim, Yong S. | Cho, A-Hyun | Shin, Hae-Eun | Kim, Yeong-In | Kim, Sang Yun | Yang, Dong Won
Article Type: Research Article
Abstract: Few studies have investigated the apolipoprotein E (APOE) ε4 allele status of dementia patients with severe white matter hyperintensities (WMH). In this study, we aimed to characterize the APOE epsivlon genotypes and clinical features of dementia patients with severe WMH. Four hundred and thirty nine patients with dementia and 152 subjects with normal cognition (NC) were recruited from multiple centers in Korea, known as the Clinical Research Center for Dementia of South Korea (CREDOS), since November 2005. The WMH were rated using the scale that had been developed by the CREDOS study. Dementia patients with minimal WMH were considered to …have Alzheimer's disease (AD) without WMH (AD-WMH: 325), and those with severe WMH were considered to have Subcortical Ischemic Vascular Dementia (SIVD: 50) or AD with severe WMH (AD+WMH: 64). Comparisons of APOE ε4 allelic prevalence were performed using chi-square analysis. The APOE ε4 allele was more prevalent in those with AD than in those with SIVD and NC (p < 0.001). It was not more prevalent in those with SIVD than in those with NC (p = 0.169). APOE ε4 allele status in AD+WMH did not differ from that in AD-WMH (p = 0.625). The APOE ε4 allele was more prevalent in those with AD than in those with SIVD. APOE ε4 may not be associated with SIVD although it is one of the vascular risk factors. Show more
Keywords: Alzheimer's disease, apolipoprotein E, vascular dementia, white matter hyperintensities
DOI: 10.3233/JAD-2011-101611
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 519-524, 2011
Authors: Yu, Guang | Li, Yi | Tian, Qing | Liu, Rong | Wang, Qun | Wang, Jian-Zhi | Wang, Xiaochuan
Article Type: Research Article
Abstract: The Chinese herb berberine has versatile health effects. Recent reports indicate that berberine has the potential to prevent and treat Alzheimer's disease (AD). In the present study, we employed tau-expressing HEK293 cells (HEK293/tau) treated with calyculin-A as a cellular model to investigate the roles of berberine in cell viability, tau phosphorylation, and oxidative stress. We found a significant reduction of calyculin A-induced tau hyperphosphorylation at Ser198/199/202, Ser396, Ser404, Thr205, and Thr231 24 h after treatment with 20 μg/ml berberine. Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3β (GSK-3β) activation, as determined by phosphatase activity assay and …GSK-3β phosphorylation at Tyr216 and Ser9, respectively. Furthermore, berberine reversed both the increase of malondialdehyde and the decrease of superoxide dismutase activity induced by calyculin A, indicating its role in anti-oxidative stress. Our findings suggest that berberine may be a potential therapeutic drug for AD. Show more
Keywords: Alzheimer's disease, berberine, GSK-3β, PP2A, tau hyperphosphorylation
DOI: 10.3233/JAD-2011-101779
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 525-535, 2011
Authors: Johansson, Per | Mattsson, Niklas | Hansson, Oskar | Wallin, Anders | Johansson, Jan-Ove | Andreasson, Ulf | Zetterberg, Henrik | Blennow, Kaj | Svensson, Johan
Article Type: Research Article
Abstract: The cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ)1-42 , T-tau, and P-tau have good diagnostic accuracy for clinically diagnosed Alzheimer's disease (AD). However, in multi-center studies, the predictive values of the CSF biomarkers have been lower, possibly due to differences in procedures for lumbar puncture and CSF handling and storage, and to differences in patient populations, clinical evaluations, and diagnostic procedures. Here we investigate the diagnostic accuracy of CSF biomarkers in a well defined homogeneous mono-center population. We also evaluate an extended panel of amyloid related biomarkers. Sixty consecutive patients admitted for cognitive impairment to a memory clinic were recruited. The …participants included patients with AD or mild cognitive impairment (MCI) diagnosed with AD upon follow-up (n = 32), patients with stable MCI (n = 13), patients with other dementias diagnosed at primary evaluation or upon follow-up (n = 15), and healthy controls (n = 20). CSF was analyzed for Aβ1-42 , T-tau, P-tau, AβX-38 , AβX-40 , AβX-42 , sAβPPα, and sAβPPβ. In multivariate analysis, the core biomarkers Aβ1-42 , T-tau, and P-tau demonstrated a high ability to diagnose AD versus the combined groups of controls and stable MCI, with an area under the receiver operating characteristic curve (AUROC) of 0.97 (95% CI 0.93–1.00, p < 0.0001). The additional biomarkers only marginally increased AUROC to 0.98 (95% CI 0.95–1.00, p < 0.0001), this increase mainly mediated by AβX-42 . In conclusion, CSF biomarkers Aβ1-42 , T-tau, and P-tau have very high diagnostic accuracy in a well defined cohort of untreated patients, demonstrating the excellent potency of CSF biomarkers to identify pathological processes in AD when a stringent analytical protocol is used. Show more
Keywords: Alzheimer's disease, amyloid, biomarkers, cerebrospinal fluid, diagnosis
DOI: 10.3233/JAD-2011-101878
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 537-546, 2011
Authors: Scheff, Stephen W. | Price, Douglas A. | Schmitt, Frederick A. | Scheff, Melissa A. | Mufson, Elliott J.
Article Type: Research Article
Abstract: Alzheimer's disease (AD) is a slowly progressing form of dementia characterized in its earliest stages as a loss of memory. Individuals with amnestic mild cognitive impairment (aMCI) may be in the earliest stages of the disease and represent an opportunity to identify pathological changes related to the progression of AD. Synaptic loss is one of the hallmarks of AD and associated with cognitive impairment. The inferior temporal gyrus plays an important role in verbal fluency, a cognitive function affected early in the onset of AD. Unbiased stereology coupled with electron microscopy was used to quantify total synaptic numbers in lamina …3 of the inferior temporal gyrus from short postmortem autopsy tissue harvested from subjects who died at different cognitive stages during the progression of AD. Individuals with aMCI had significantly fewer synapses (36%) compared to individuals with no cognitive impairment. Individuals with AD showed a loss of synapses very similar to the aMCI cohort. Synaptic numbers correlated highly with Mini Mental State Examination scores and a test of category verbal fluency. These results demonstrate that the inferior temporal gyrus is affected during the prodromal stage of the disease and may underlie some of the early AD-related clinical dysfunctions. Show more
Keywords: Dementia, language, synapses, verbal fluency
DOI: 10.3233/JAD-2011-101782
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 547-557, 2011
Authors: Marengoni, Alessandra | Fratiglioni, Laura | Bandinelli, Stefania | Ferrucci, Luigi
Article Type: Research Article
Abstract: Thousand and twelve dementia-free elderly (60–98 years old) enrolled in the InChianti Study (Italy) were evaluated at baseline (1998–2000) and at 3-year follow-up (2001–2003) with the aim of analyzing the association of lifetime socioeconomic status (SES) with prevalent and incident cognitive impairment no-dementia (CIND). SES was defined from information on formal education, longest held occupation, and financial conditions through life. CIND was defined as age-adjusted Mini-Mental State Examination score one standard deviation below the baseline mean score of participants without dementia. Logistic regression and Cox proportional-hazards models were used to estimate the association of SES with CIND. Demographics, occupation characteristics …(i.e., job stress and physical demand), cardiovascular diseases, diabetes, apolipoprotein E (APOE) genotype, smoking, alcohol consumption, depressive symptoms, and C-reactive protein were considered potential confounders. Prevalence of CIND was 17.7%. In the fully adjusted model, low education (OR = 2.1; 95% confidence intervals, CI = 1.4 to 3.2) was associated with prevalent CIND. Incidence rate of CIND was 66.0 per 1000 person-years. Low education (HR = 1.7; 95% CI = 1.04 to 2.6) and manual occupation (HR = 1.9; 95% CI = 1.0 to 3.6) were associated with incident CIND. Among covariates, high job-related physical demand was associated with both prevalent and incident CIND (OR = 1.6; 95% CI = 1.1 to 2.4 and HR = 1.5; 95% CI = 1.0 to 2.3). After stratification for education, manual occupation was still associated with CIND among participants with high education (HR = 2.2; 95% CI = 1.2 to 4.3 versus HR = 1.4; 95% CI = 0.2 to 10.4 among those with low education). Proxy markers of lifetime SES (low education, manual occupation and high physical demand) are cross-sectional correlates of CIND and predict incident CIND over a three-year follow-up. Show more
Keywords: Cognitive impairment no-dementia, epidemiology, education, finances, occupation, socioeconomic status
DOI: 10.3233/JAD-2011-101863
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 559-568, 2011
Authors: Antonini, Vuokko | Marrazzo, Agostino | Kleiner, Giulio | Coradazzi, Marino | Ronsisvalle, Simone | Prezzavento, Orazio | Ronsisvalle, Giuseppe | Leanza, Giampiero
Article Type: Research Article
Abstract: Sigma-1 receptor agonists have recently attracted much attention as potential therapeutic drugs for cognitive and affective disorders, however, it is still unclear whether they act via modulation of transmitter release or activation of sigma-1 receptors in memory-related brain regions. In the present study, we have investigated the anti-amnesic and neuroprotective actions of the compound (-)-methyl (1S,2R)-2-{[1-adamantyl(methyl)amino]methyl}-1-phenylcyclopropane-carboxylate) [(-)-MR22], a selective sigma-1 receptor agonist able to protect cultured cortical neurons from amyloid toxicity. To this aim, cognitive deficits, cholinergic loss, and amyloid peptide accumulation were obtained in the rat by simultaneous injections of a selective immunotoxin and pre-aggregated amyloid peptide into the …basal forebrain and the hippocampus, respectively. At about five–six weeks post-lesion, the double-lesioned animals exhibited dramatic deficits in spatial learning and memory, whereas animals with single injections of either compound were not or only marginally affected, in spite of equally severe cholinergic loss or amyloid deposition. Administration of (-)-MR22 appeared to reverse cognitive impairments in double lesioned animals, whereas pre-treatment with the selective sigma-1 antagonist BD1047 abolished this effect. Moreover, (-)-MR22 normalized the levels of cell-associated amyloid-β protein precursor (AβPP) in the neocortex and hippocampus, thus sustaining a non-amyloidogenic AβPP processing. By contrast, treatment with (-)-MR22 produced no effects whatsoever in intact animals. Thus, sigma-1 receptor agonists such as (-)-MR22 may ameliorate perturbed cognitive abilities and exert a protective action onto target neurons, holding promises as viable tools for memory enhancement and neuroprotection. Show more
Keywords: Acetylcholine, Alzheimer's disease, amyloid, animal model, immunotoxin, sigma-1 receptor agonist, spatial learning, rat
DOI: 10.3233/JAD-2011-101794
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 569-586, 2011
Authors: Belbin, Olivia | Brown, Kristelle | Shi, Hui | Medway, Christopher | Abraham, Richard | Passmore, Peter | Mann, David | Smith, A. David | Holmes, Clive | McGuinness, Bernadette | Craig, David | Warden, Donald | Heun, Reinhard | Kölsch, Heike | Love, Seth | Kalsheker, Noor | Williams, Julie | Owen, Michael J. | Carrasquillo, Minerva | Younkin, Steven | Morgan, Kevin | Kehoe, Patrick G.
Article Type: Research Article
Abstract: A key pathological feature of late-onset Alzheimer's disease (LOAD) is the abnormal extracellular accumulation of the amyloid-β (Aβ) peptide. Thus, altered Aβ degradation could be a major contributor to the development of LOAD. Variants in the gene encoding the Aβ-degrading enzyme, angiotensin-1 converting enzyme (ACE) therefore represent plausible candidates for association with LOAD pathology and risk. Following Alzgene meta-analyses of all published case-control studies, the ACE variants rs4291 and rs1800764 showed significant association with LOAD risk. Furthermore ACE haplotypes are associated with both plasma ACE levels and LOAD risk. We tested three ACE variants (rs4291, rs4343, and rs1800764) for association …with LOAD in ten Caucasian case-control populations (n = 8,212). No association was found using multiple logistic models (all p > 0.09). We found no population heterogeneity (all p > 0.38) or evidence for association with LOAD risk following meta-analysis of the ten populations for rs4343 (OR = 1.00), rs4291 (OR = 0.97), or rs1800764 (OR = 0.99). Although we found no haplotypic association in our complete dataset (p = 0.51), a significant global haplotypic p-value was observed in one population (p = 0.007) due to an association of the H3 haplotype (OR = 0.72, p = 0.02) and a trend towards an association of H4 (OR = 1.38, p = 0.09) and H7 (OR = 2.07, p = 0.08) although these did not survive Bonferroni correction. Previously reported associations of ACE variants with LOAD will be diminished following this study. At best, ACE variants have modest effect sizes, which are likely part of a complex interaction between genetic, phenotypic and pharmacological effects that would be undetected in traditional case-control studies. Show more
Keywords: Alzheimer's disease, angiotensin-1 converting enzyme, haplotype, heterogeneity, late onset, meta-analysis
DOI: 10.3233/JAD-2011-101914
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 587-597, 2011
Authors: Bloudek, Lisa M. | Spackman, D. Eldon | Veenstra, David L. | Sullivan, Sean D.
Article Type: Research Article
Abstract: Cholinesterase inhibitors and memantine are medications used in the treatment of Alzheimer's disease (AD). These agents have been shown to reduce the rate of AD progression in randomized trials. The objective of this study is to evaluate the association between treatment with cholinesterase inhibitors or memantine and the probability of transitioning to a more severe Clinical Dementia Rating (CDR) state. Analysis was limited to possible or probable AD patients from NACC-UDS with three or more observations, baseline CDR score of 0.5 or 1, and without reported use AD drugs at enrollment. Use of an AD drug at any observation after …baseline was classified as treatment. Odds of CDR stage were calculated by multinomial logistic regression controlling for baseline age, baseline MMSE score, education, marital status, race, gender, place of residence, and time since last measure. The resulting coefficients from logistic regression were used to calculate transitional probabilities. A total of 1,114 patients were included. No differences were observed in the probability of transitioning to more severe CDR states based on treatment, but treated patients had lower odds of death, OR 0.49 (95% CI 0.31 to 0.79) compared to untreated. Ultimately, this study failed to detect a difference in the probability of progressing to a more severe AD state as a result of treatment in an observational cohort of AD patients, but is limited by non-randomized treatment selection and small dataset. The NACC-UDS dataset is ongoing and this analysis may be improved if repeated when more data is available. Show more
Keywords: Alzheimer's disease, disease progression, drug therapy, economic, models, probability
DOI: 10.3233/JAD-2011-101758
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 599-607, 2011
Authors: Lerner, Alan Jay
Article Type: Book Review
DOI: 10.3233/JAD-2011-110003
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 609-609, 2011
Article Type: Other
DOI: 10.3233/JAD-2011-101759
Citation: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 611-613, 2011
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl